CAR T-cell Therapy for Lung Cancer and Malignant Pleural Mesothelioma

Overview

Journal Transl Res

Publisher Elsevier

Specialty Pathology

Date 2017 May 16

PMID 28502785

Citations 59

Authors

Masha Zeltsman

Jordan Dozier

Erin McGee

Daniel Ngai

Prasad S Adusumilli

Affiliations

Soon will be listed here.

Abstract

Immunotherapy is a promising field that harnesses the power of the immune system as a therapeutic agent for cancer treatment. Beneficial outcomes shown in patients with non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma (MPM) with relatively higher tumor-infiltrating T cells, combined with impressive responses obtained in a cohort of patients with NSCLC following checkpoint blockade therapy, lays a strong foundation to promote effector immune responses in these patients. One such approach being investigated is administration of tumor antigen-targeted T cells with transduction of a chimeric antigen receptor (CAR). CARs are synthetic receptors that enhance T-cell antitumor effector function and have gained momentum to investigate in solid tumors based on recent successes of clinical trials treating patients with B-cell hematologic malignancies. This review summarizes target antigens for CAR T-cell therapy that are being investigated in preclinical studies and clinical trials for both NSCLC and MPM patients. We discuss the rationale for combination immunotherapies for NSCLC and MPM patients. Additionally, we have highlighted the challenges and strategies for overcoming the obstacles facing translation of CAR T-cell therapy to solid tumors.

Citing Articles

[Modification with IL-21 and CCL19 enhances killing efficiency and tumor infiltration of NKP30 CAR-T cells in lung cancer].

Zhou Z, Liu S, Li J, Chen M, Lin H, Chen Y Nan Fang Yi Ke Da Xue Xue Bao. 2024; 44(10):1926-1936.

PMID: 39523093 PMC: 11526451. DOI: 10.12122/j.issn.1673-4254.2024.10.11.

Development of Personalized Strategies for Precisely Battling Malignant Melanoma.

Isaak A, Clements G, Buenaventura R, Merlino G, Yu Y Int J Mol Sci. 2024; 25(9).

PMID: 38732242 PMC: 11084485. DOI: 10.3390/ijms25095023.

Immune modulation in malignant pleural effusion: from microenvironment to therapeutic implications.

Ge S, Zhao Y, Liang J, He Z, Li K, Zhang G Cancer Cell Int. 2024; 24(1):105.

PMID: 38475858 PMC: 10936107. DOI: 10.1186/s12935-024-03211-w.

Harnessing Chimeric Antigen Receptor-engineered Invariant Natural Killer T Cells: Therapeutic Strategies for Cancer and the Tumor Microenvironment.

Wang Y, Li Y Curr Pharm Biotechnol. 2024; 25(15):2001-2011.

PMID: 38310449 DOI: 10.2174/0113892010265228231116073012.

Immunological subtyping of salivary gland cancer identifies histological origin-specific tumor immune microenvironment.

Hong J, Choi E, Kim D, Seo M, Kang H, Park B NPJ Precis Oncol. 2024; 8(1):15.

PMID: 38245623 PMC: 10799913. DOI: 10.1038/s41698-024-00501-4.

References

Cooper L, Ausubel L, Gutierrez M, Stephan S, Shakeley R, Olivares S . Manufacturing of gene-modified cytotoxic T lymphocytes for autologous cellular therapy for lymphoma. Cytotherapy. 2006; 8(2):105-17. DOI: 10.1080/14653240600620176. View

Liu X, Ranganathan R, Jiang S, Fang C, Sun J, Kim S . A Chimeric Switch-Receptor Targeting PD1 Augments the Efficacy of Second-Generation CAR T Cells in Advanced Solid Tumors. Cancer Res. 2016; 76(6):1578-90. PMC: 4800826. DOI: 10.1158/0008-5472.CAN-15-2524. View

Rosell R, Karachaliou N, Wolf J, Ou S . ALK and ROS1 non-small-cell lung cancer: two molecular subgroups sensitive to targeted therapy. Lancet Respir Med. 2014; 2(12):966-8. DOI: 10.1016/S2213-2600(14)70259-0. View

Feng K, Guo Y, Dai H, Wang Y, Li X, Jia H . Chimeric antigen receptor-modified T cells for the immunotherapy of patients with EGFR-expressing advanced relapsed/refractory non-small cell lung cancer. Sci China Life Sci. 2016; 59(5):468-79. DOI: 10.1007/s11427-016-5023-8. View

van der Stegen S, Hamieh M, Sadelain M . The pharmacology of second-generation chimeric antigen receptors. Nat Rev Drug Discov. 2015; 14(7):499-509. PMC: 6410718. DOI: 10.1038/nrd4597. View

Di Stasi A, Tey S, Dotti G, Fujita Y, Kennedy-Nasser A, Martinez C . Inducible apoptosis as a safety switch for adoptive cell therapy. N Engl J Med. 2011; 365(18):1673-83. PMC: 3236370. DOI: 10.1056/NEJMoa1106152. View

Zhao Y, Moon E, Carpenito C, Paulos C, Liu X, Brennan A . Multiple injections of electroporated autologous T cells expressing a chimeric antigen receptor mediate regression of human disseminated tumor. Cancer Res. 2010; 70(22):9053-61. PMC: 2982929. DOI: 10.1158/0008-5472.CAN-10-2880. View

Servais E, Colovos C, Rodriguez L, Bograd A, Nitadori J, Sima C . Mesothelin overexpression promotes mesothelioma cell invasion and MMP-9 secretion in an orthotopic mouse model and in epithelioid pleural mesothelioma patients. Clin Cancer Res. 2012; 18(9):2478-89. PMC: 3759995. DOI: 10.1158/1078-0432.CCR-11-2614. View

Sadelain M, Riviere I, Brentjens R . Targeting tumours with genetically enhanced T lymphocytes. Nat Rev Cancer. 2003; 3(1):35-45. DOI: 10.1038/nrc971. View

10.

NORTH R . Cyclophosphamide-facilitated adoptive immunotherapy of an established tumor depends on elimination of tumor-induced suppressor T cells. J Exp Med. 1982; 155(4):1063-74. PMC: 2186638. DOI: 10.1084/jem.155.4.1063. View

11.

Ruella M, Barrett D, Kenderian S, Shestova O, Hofmann T, Perazzelli J . Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapies. J Clin Invest. 2016; 126(10):3814-3826. PMC: 5096828. DOI: 10.1172/JCI87366. View

12.

Thomas A, Chen Y, Steinberg S, Luo J, Pack S, Raffeld M . High mesothelin expression in advanced lung adenocarcinoma is associated with KRAS mutations and a poor prognosis. Oncotarget. 2015; 6(13):11694-703. PMC: 4484487. DOI: 10.18632/oncotarget.3429. View

13.

Wallace A, Kapoor V, Sun J, Mrass P, Weninger W, Heitjan D . Transforming growth factor-beta receptor blockade augments the effectiveness of adoptive T-cell therapy of established solid cancers. Clin Cancer Res. 2008; 14(12):3966-74. PMC: 2491721. DOI: 10.1158/1078-0432.CCR-08-0356. View

14.

Servais E, Suzuki K, Colovos C, Rodriguez L, Sima C, Fleisher M . An in vivo platform for tumor biomarker assessment. PLoS One. 2011; 6(10):e26722. PMC: 3202552. DOI: 10.1371/journal.pone.0026722. View

15.

Dudley M, Wunderlich J, Robbins P, Yang J, Hwu P, Schwartzentruber D . Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science. 2002; 298(5594):850-4. PMC: 1764179. DOI: 10.1126/science.1076514. View

16.

Dudley M, Wunderlich J, Yang J, Sherry R, Topalian S, Restifo N . Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol. 2005; 23(10):2346-57. PMC: 1475951. DOI: 10.1200/JCO.2005.00.240. View

17.

Sadelain M . CAR therapy: the CD19 paradigm. J Clin Invest. 2015; 125(9):3392-400. PMC: 4588281. DOI: 10.1172/JCI80010. View

18.

Davila M, Riviere I, Wang X, Bartido S, Park J, Curran K . Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci Transl Med. 2014; 6(224):224ra25. PMC: 4684949. DOI: 10.1126/scitranslmed.3008226. View

19.

Maus M, Haas A, Beatty G, Albelda S, Levine B, Liu X . T cells expressing chimeric antigen receptors can cause anaphylaxis in humans. Cancer Immunol Res. 2014; 1(1):26-31. PMC: 3888798. DOI: 10.1158/2326-6066.CIR-13-0006. View

20.

Villena-Vargas J, Adusumilli P . Mesothelin-targeted immunotherapies for malignant pleural mesothelioma. Ann Cardiothorac Surg. 2013; 1(4):466-71. PMC: 3741795. DOI: 10.3978/j.issn.2225-319X.2012.10.03. View